If authorized by the US FDA, Novavax, Inc.’s 2023-2024 COVID vaccine can go to market without another meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.
The language of the ACIP’s 12 September 2023 universal recommendation for updated COVID vaccines available under BLAs or emergency use...







